Clinical trial NCT02735629: Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
Official title: Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Opiate Induced Respiratory Depression
Lead sponsor: RespireRx
Sponsor class: INDUSTRY
Collaborators: name: Duke University
First posted: 2016-04-13
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil. The study will also investigate whether ascending doses of CX1739 reduce the analgesic effect of remifentanil or alter the BIS measure of sedation and will evaluate the safety of CX1739 when used in conjunction with remifentanil.


Eligibility criteria: Inclusion Criteria:

* To be eligible for this trial, subjects must meet all of the following criteria:

  1. Males 18 to 50 years of age, inclusive
  2. Body mass index of 18.0 to 30.0 kg/m2, inclusive, using the formula: weight (kg)/height (m)2
  3. Healthy, as determined by medical history, physical examination including vital signs, and clinical laboratory test results
  4. American Society of Anesthesiologists Physical Status Classification 1
  5. Willing and able to provide voluntary, written informed consent

Exclusion Criteria:

* If a subject meets any of the following criteria, he cannot be enrolled in the study:

  1. History of any chronic illness or evidence of clinically significant organic or psychiatric disease on medical history or physical examination which, in the opinion of the principal investigator (PI), would confound the study results or present a risk to the subject
  2. Acute illness within 2 weeks before dosing
  3. History of any clinically significant pulmonary condition (eg, asthma) within the last 2 years requiring admission to the hospital
  4. Previous diagnosis of obstructive sleep apnea based on polysomnography
  5. Currently using any prescription medication or use within the last 30 days
  6. Laboratory values (clinical chemistry, hematology, urinalysis) outside the laboratory reference range considered clinically significant (NOTE: in the event of any parameter lying outside of the normal range, the sample may be repeated once; this value will be accepted if it lies within the normal range)
  7. Presence of QT interval corrected \> 440 msec on ECG
  8. Resting HR while awake \< 45 or \> 90 beats/minute
  9. History of daily use of tobacco or other nicotine-containing products within 1 year of study entry or positive cotinine test at screening and subsequent study visits
  10. History of allergic hypersensitivity to ampakines (CX717, CX1739), remifentanil, naloxone, or any component of these formulations; history of multiple drug allergies
  11. History or current evidence of abuse of any drug substance, licit or illicit, including alcohol; positive urine drug screen (UDS) for drugs of abuse at screening
  12. Inability to understand the protocol requirements; instructions; study-related restrictions; or nature, scope, and possible consequences of the study
  13. Unlikely to complete the study, eg, because of inability to return for follow-up visits
  14. Participation in another study with any investigational drug in the 3 months preceding this study
  15. Blood or plasma donation of more than 500 mL during the month before randomization and more than 50 mL in the 2 weeks before randomization

Primary outcomes:
measure: Respiratory depression
timeFrame: Sequence #1 - 30 minutes
Secondary outcomes:
measure: Pain tolerance threshold
timeFrame: Sequence #2 - 20 minutes
measure: Maintenance of sedation
timeFrame: Sequence #1 - 30 minutes
measure: The number of patients that experience an adverse drug reaction upon ingestion of CX1739 when used alone or in conjunction with remifentanil
timeFrame: up to 5 weeks
measure: Change in pupil size
timeFrame: Sequence #2 - 20 minutes
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke Clinical Research Unit
state: North Carolina
Study officials:
affiliation: RespireRx Pharmaceuticals
name: Richard Purcell
role: STUDY_DIRECTOR
References: